Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paramananthan Mariappan

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
Journal of Cancer Policy|September 7, 2024
Emergency and non-emergency routes to cancer diagnoses in 2020 and 2021: A Population-based study of 154,863 patientsCalum Purdie, Gavin R C Clark, David A Cameron, et al.
European Urology Open Science|July 13, 2023
Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in Participants with a First Suspected Diagnosis of Intermediate- or High-risk Non-muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a Randomised Controlled TrialGe Yu, Stephen Rice, Rakesh Heer, et al.
BJU International|November 3, 2011
Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarkingParamananthan Mariappan, Steven M Finney, Elizabeth Head, et al.
BJUI Compass|June 30, 2026
State of the nation: Understanding the current NHS treatment pathway to identify opportunities to advance future care of patients with high-risk non-muscle invasive bladder cancer in the UK (SPAN-UK)Jonathan Aning, James W F Catto, Rebecca Martin, et al.
BJU International|January 15, 2021
What influences adherence to guidance for postoperative instillation of intravesical chemotherapy to patients with bladder cancer?Jennifer Dunsmore, Eilidh Duncan, Paramananthan Mariappan, et al.
European Urology|July 9, 2014
Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendationsJ Alfred Witjes, Marek Babjuk, Paolo Gontero, et al.
Investigative and Clinical Urology|November 3, 2025
Evaluating diagnostic performance of urinary biomarkers in the surveillance of non-muscle invasive bladder carcinoma: A systematic reviewReena Prhiya Ramasamy, Chu Ann Chai, Angelo Cormio, et al.
European Urology|July 22, 2020
Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators ProgrammeParamananthan Mariappan, Allan Johnston, Luisa Padovani, et al.
BJU International|January 21, 2023
Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real-world findings from NHS England between 2013 and 2019James W F Catto, Olena Mandrik, Lewis A Quayle, et al.
European Urology|August 23, 2022
Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled TrialWei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
Journal of Cancer Policy|September 7, 2024
Emergency and non-emergency routes to cancer diagnoses in 2020 and 2021: A Population-based study of 154,863 patientsCalum Purdie, Gavin R C Clark, David A Cameron, et al.
European Urology Open Science|July 13, 2023
Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in Participants with a First Suspected Diagnosis of Intermediate- or High-risk Non-muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a Randomised Controlled TrialGe Yu, Stephen Rice, Rakesh Heer, et al.
BJU International|November 3, 2011
Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarkingParamananthan Mariappan, Steven M Finney, Elizabeth Head, et al.
BJUI Compass|June 30, 2026
State of the nation: Understanding the current NHS treatment pathway to identify opportunities to advance future care of patients with high-risk non-muscle invasive bladder cancer in the UK (SPAN-UK)Jonathan Aning, James W F Catto, Rebecca Martin, et al.
BJU International|January 15, 2021
What influences adherence to guidance for postoperative instillation of intravesical chemotherapy to patients with bladder cancer?Jennifer Dunsmore, Eilidh Duncan, Paramananthan Mariappan, et al.
European Urology|July 9, 2014
Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendationsJ Alfred Witjes, Marek Babjuk, Paolo Gontero, et al.
Investigative and Clinical Urology|November 3, 2025
Evaluating diagnostic performance of urinary biomarkers in the surveillance of non-muscle invasive bladder carcinoma: A systematic reviewReena Prhiya Ramasamy, Chu Ann Chai, Angelo Cormio, et al.
European Urology|July 22, 2020
Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators ProgrammeParamananthan Mariappan, Allan Johnston, Luisa Padovani, et al.
BJU International|January 21, 2023
Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real-world findings from NHS England between 2013 and 2019James W F Catto, Olena Mandrik, Lewis A Quayle, et al.
European Urology|August 23, 2022
Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled TrialWei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al.
Pageof 7